International

Master in Sustainable

Drug Discovery


Master in short

2 years

The S-DISCO programme is a 2-year full-time Master programme.

4 universities

The programme is organized by 4 European universities, i.e. Ghent University, Medical University of Gdańsk, University of Lille and the University of Groningen.

Master thesis

Students will perform a master thesis in one of the partner institutions or with one of the numerous associated partners (incl. industry, competent authorities and research institutions).

Master degree

Successful students will obtain a common master of science degree of the partner universities.

Target students

Candidates must hold a higher education diploma (180 ECTS or higher) in Chemical, Biological, (Bio-)Engineering, Pharmaceutical or Medical sciences.

Get involved


S-DISCO Programme

Learn about the S-DISCO programme and how to apply.

Our partners

The S-DISCO master degree has been built through close collaboration between the consortium and industrial players in the field in order to train high-level graduates with inter-and trans-disciplinary skills in the different fields of drug discovery, with a focus on sustainability. The partners will actively participate in the S-DISCO programme by i.a. teaching, holding seminars and providing internships to master thesis students. Discover our partners

What to expect?

Find out what students can expect when they are selected for the S-DISCO programme.

News


Research presented at the 16th Conference of the Parties to the Convention on Biological Diversity (COP16) in Cali emphasized an urgent call to address biodiversity challenges. "If we don’t take immediate action, these ecosystems are already on the verge of irreversible change," warns Manuel Pulgar-Vidal, global climate and energy lead at WWF. Take a look […]
November 3rd 2024 was the One Health day, reminding us of the connection between human, animal and environmental health. Have a look here for more information.
Merck & Co., Inc. is being recognized for developing a new “continuous process” for manufacturing its PD-1 therapy, KEYTRUDA® (pembrolizumab). Typically, these types of proteins are produced in large batches. Merck now uses a continuous process to produce pembrolizumab, in which the protein is filtered away from the cells continuously instead of performing a one-time […]

"Finding adequate treatments for unmet disease conditions, for everyone, everywhere, at a fair price, while respecting the environment and ecosystems is an enormous challenge, and one that we must be better prepared for."

Bart De Spiegeleer, Ghent University

Scroll to Top